Literature DB >> 187785

Immunotherapy of cancer with nonliving mycobacteria and cord factor (trehalose-6,6'-dimycolate) in aqueous medium.

A Bekierkunst.   

Abstract

Heat-killed BCG, cord factor (trehalose-6,6'-dimycolate), or killed BCG plus cord factor in aqueous medium, admixed with tumor cells and injected into the skin of guinea pigs, inhibited the growth of a hepatocellular carcinoma. Intralesional administration of killed BCG or Mycobacterium kansasii coated with cord factor, in the same medium, caused regression of established tumors in 48 and 45% of the treated animals, respectively.

Entities:  

Mesh：

Year:  1976        PMID： 187785     DOI： 10.1093/jnci/57.4.963

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


  5 in total

1.  Immunotherapy of a guinea pig hepatoma with mycobacterial vaccines: comparison of BCG cell walls and cell wall skeletons.

Authors:  E Yarkoni; H J Rapp
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

2.  Immunotherapy of guinea pig line 10 hepatoma with nonliving BCG cells in aqueous medium.

Authors:  A Bekierkunst; M B Goren
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

3.  Parallel antitumor, granuloma-forming and tumor-necrosis-factor-priming activities of mycoloyl glycolipids from Nocardia rubra that differ in carbohydrate moiety: structure-activity relationships.

Authors:  Y Natsuhara; S Oka; K Kaneda; Y Kato; I Yano
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Effect of intralesional and systemic BCG-application or a combined cyclophosphamide/BCG treatment on experimental bladder cancer.

Authors:  H D Adolphs; J Thiele; H Kiel
Journal:  Urol Res       Date:  1979-06-22

5.  Influence of type of oil and surfactant concentration on the efficacy of emulsified Mycobacterium bovis BCG cell walls to induce tumor regression in guinea pigs.

Authors:  E Yarkoni; H J Rapp
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.